海正药业：公司特治星二期扩产项目预计将于明年上半年可以实现商业化生产

Core Viewpoint - Pfizer voluntarily canceled the drug registration certificate for injectable piperacillin-tazobactam, which may positively impact the sales of the product "Tezhixing" by Haizheng Pharmaceutical [1] Group 1: Company Actions - Haizheng Pharmaceutical confirmed that the technology and rights for "Tezhixing" have been transferred to Hanhui Pharmaceutical, which is now the legal holder of the drug's market license in China [1] - The product "Tezhixing" has achieved local production under Pfizer's guidance, ensuring that its quality is consistent with the original product [1] Group 2: Market Impact - The product has already completed the market replacement of the original imported product and has established a continuous supply capability [1] - Haizheng Pharmaceutical's second-phase expansion project for "Tezhixing" is expected to achieve commercial production in the first half of next year [1]